Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)

NCT00996853 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00996853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00996853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
October 31, 2009
Completion date
April 6, 2011
Enrollment
9,206 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

influenza